Pediatric Neuroblastoma Treatment Market Size, Share & Industry Analysis, By Treatment Type (Immunotherapy, Chemotherapy, Radiation Therapy, Others), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2024-2032

Neuroblastoma is a cancerous tumor that initiates in the nerve cells outside the brain of infants and young children. It can begin in the nerve tissue near the spine in the neck, abdomen, pelvis, or chest but it most often begins in the adrenal gland. Neuroblastoma develops most often in infants and children younger than the age of 5. Neuroblasts are the immature nerve cells found in the unborn babies which normally mature into the nerve cells or adrenal medulla cells. Neuroblastoma forms when these neuroblasts do not mature properly and continue to grow to form a mass called a tumor. It usually develops due to the inherited gene mutations passed from the parent to the child. Also the genetic changes, called single nucleotide polymorphisms (SNPs), contribute to the development of neuroblastoma in children who do not have a family history.

Some of the most common symptoms of neuroblastoma are firm mass in the abdomen, enlarged stomach, anaemia, crankiness, fever, bone pain, bulging eyes, dark circles around the eyes, weakness and high blood pressure. Strong pipeline of the products, and favourable reimbursement scenario in many countries of the region are likely to generate revenue from pediatric neuroblastoma treatment products during the forecast period.

Increasing prevalence of pediatric neuroblastoma, growing awareness about the treatment among the population across the globe, advancement in technology, and improvement in healthcare infrastructure of emerging regions are the factors that are driving the market growth. According to the American Society of Clinical Oncology (ASCO), neuroblastoma is the third most common cancer in children in the U.S. and accounts for 6% of all childhood cancers which is expected to generate demand for effective treatment options for the treatment of neuroblastoma in children.

However, high costs and the side effects associated with the treatment options such as hair loss, fatigue, skin reactions, diarrhoea, etc. hamper the growth of pediatric neuroblastoma treatment market.

Key Players Covered:

The major companies in the global pediatric neuroblastoma market report include United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES INC., PROVECTUS BIOPHARMACEUTICALS, INC., Pfizer Inc., MacroGenics, Inc., Bayer AG, and other prominent players.

Key Insights

• Prevalence of Pediatric Neuroblastoma by Key Countries/Regions


• New Product Launches


• Reimbursement Scenario


• Recent Industry Developments Such as Mergers, Partnerships, and Acquisitions

Regional Analysis:

The global pediatric neuroblastoma treatment market is likely to be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is projected to lead the global pediatric neuroblastoma treatment market due to rising prevalence of pediatric neuroblastoma in U.S. According to American Society of Clinical Oncology (ASCO), neuroblastoma is the third most common cancer, accounting for 6% of all childhood cancers in children in the U.S. Thus, growing incidence of pediatric neuroblastoma in the region is expected to fuel the market growth during forecast period. The pediatric neuroblastoma treatment market is expected to hold the second largest share in the upcoming years.

Also, the availability of advanced healthcare facilities and growing investments in research and development are likely to contribute to the market growth. The market in Asia Pacific and Latin America region are expected to register a fast growth during the forecast period due to the increasing number of pediatric neuroblastoma cases and improving healthcare infrastructure. The Middle East and Africa is anticipated to register substantial market growth by the end of the forecast period.

Segmentation

Pediatric Neuroblastoma Treatment Industry Developments

• In Oct 2019, Y-mAbs Therapeutics, Inc. announced a clinical update on naxitamab for the treatment of neuroblastoma and osteosarcoma at the International Society of Pediatric Oncology (SIOP) Annual Congress held in Lyon, France


• In November 2018, United Therapeutics Corporation got Health Canada approval for Unituxin for the treatment of high-risk pediatric neuroblastoma.


• In November 2018, PROVECTUS BIOPHARMACEUTICALS, INC. got U.S. FDA approval for small molecule oncolytic immunotherapy PV-10 for the treatment of pediatric neuroblastoma.